Barry R. Keith

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan et al. · Cancer Research · 2006 · 904 citations

Breast Oncology, Oncology, Medicine +11

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 737 citations

Pathology, Cell Proliferation, Cell Growth +16

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 664 citations

Oncology, Medicine, Receptor Tyrosine Kinase +8

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Potential Therapy, Tumor Biology, Oncology +18

Inhibition of colony-stimulating-factor-1 signaling<i>in vivo</i>with the orally bioavailable cFMS kinase inhibitor GW2580

James G. Conway, Brad McDonald, Janet H. Parham et al. · Proceedings of the National Academy of Sciences · 2005 · 252 citations · Full text